JARISLOWSKY FRASER Ltd Has $222.76 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

JARISLOWSKY FRASER Ltd lowered its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 9.0% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,519,272 shares of the medical equipment provider's stock after selling 249,994 shares during the period. JARISLOWSKY FRASER Ltd owned approximately 0.17% of Boston Scientific worth $222,755,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. TFC Financial Management Inc. increased its stake in Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 210 shares during the period. Colonial Trust Co SC increased its stake in Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 260 shares during the period. West Oak Capital LLC bought a new stake in Boston Scientific in the fourth quarter valued at about $29,000. Valley National Advisers Inc. increased its stake in Boston Scientific by 262.4% in the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 286 shares during the period. Finally, Fairway Wealth LLC bought a new stake in Boston Scientific in the fourth quarter valued at about $36,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total value of $16,852,118.64. Following the transaction, the chief executive officer now directly owns 1,535,706 shares of the company's stock, valued at approximately $157,379,150.88. This trade represents a 9.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP John Bradley Sorenson sold 4,572 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the transaction, the executive vice president now directly owns 18,705 shares in the company, valued at approximately $1,955,420.70. The trade was a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 267,021 shares of company stock valued at $27,534,636. 0.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

BSX has been the topic of a number of analyst reports. Royal Bank of Canada upped their target price on shares of Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Wells Fargo & Company upped their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. BTIG Research reaffirmed a "buy" rating and set a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, April 23rd. Morgan Stanley upped their price objective on shares of Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. Finally, Needham & Company LLC upped their price objective on shares of Boston Scientific from $113.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Twenty-three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $114.52.

Boston Scientific Price Performance

Shares of BSX traded down $0.14 during mid-day trading on Wednesday, hitting $102.81. 5,737,879 shares of the company traded hands, compared to its average volume of 6,348,700. Boston Scientific Co. has a one year low of $71.88 and a one year high of $107.17. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The business has a 50-day moving average of $98.76 and a 200 day moving average of $96.28. The stock has a market capitalization of $152.10 billion, a price-to-earnings ratio of 82.25, a PEG ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. During the same period in the prior year, the firm earned $0.56 earnings per share. Boston Scientific's revenue was up 20.9% compared to the same quarter last year. As a group, equities analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.